Kyowa Kirin Pays $100M Upfront to BridgeBio for Skeletal Dysplasias Drug in Japan

By /

Kyowa Kirin’s dealmaking continued on Wednesday when BridgeBio Pharma granted the Japanese company an exclusive license to develop and commercialize infigratinib.

Scroll to Top